Vinehealth, a London, UK-based digital health platform, raised $5.5m in seed funding.
The round was led by Talis Capital, with participation from previous investors Playfair Capital and Ascension, and a number of angels including Keith Gibbs, former CEO of AXA PPP Healthcare; Pam Garside, partner at Newhealth; VOYAGERS Health-Tech Fund, led by David Rowan, founding editor of WIRED; David Giampaolo, healthcare entrepreneur and founder of PI Capital; Deepali Nangia, venture partner at Speedinvest and Atomico Angel; Faisal Mehmud, Vice President and former Medical Director of Bristol Myers Squibb; and KHP, a collaboration between King’s College London, King’s College Hospital NHS Foundation Trust and Guy’s and St Thomas’ NHS Trust.
The company intends to use the funds to further develop its product, scale its team and expand in the US.
Founded in 2018 by Rayna Patel and Georgina Kirby, Vinehealth is a digital health platform for cancer patients. Using a combination of behavioural science and AI, the company’s intelligent digital technology provides scalable patient support programmes and collects data. Using its app, patients can self-manage their medications, side-effects and symptoms, and can regularly enter ‘patient-reported outcome’ (PRO) data to support clinical decision-making, inform service delivery and drive clinical research. This data can be used by pharmaceutical companies, insurers and hospitals.
Vinehealth is adherent to GDPR requirements and collation and appropriate secondary use of de-identified data.